Cite
HARVARD Citation
Grob, J. et al. (n.d.). 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). European journal of cancer. pp. S682-S683. [Online].